Abortion Pill Mifepristone Has Its Day(s) In Court

This episode is brought to you by Semafor Healthcare.

Delivered weekly from David Lim, Semafor Healthcare connects the dots between decisions in government, business, and technology to reveal how they impact the future of healthcare. Each edition will provide the analysis you need to understand and stay ahead of a rapidly changing landscape. Subscribe for free.

Health Affairs' Leslie Erdelack and Jessica Bylander discuss the large amount of news and controversy over the abortion pill mifepristone as the drug's 2000 approval -- and subsequent changes to how patients can access it -- make their way through the courts.

NOTE: This episode was recorded in the afternoon of April 13, 2023, shortly before the Justice Department requested the Supreme Court to restore access to the mifepristone.

Related Links:

• FDA's Liberalization of Mifepristone Dispensing: Securing The Future Of Access To Medical Abortion (Health Affairs Forefront)
• Drugmakers sign letter supporting FDA and calling for reversal of Texas judge's mifepristone ruling (CNN)
• Abortion Medication Mifepristone Will Remain Legal for Now, but With More Restrictions (Vanity Fair)
• United States Department of Justice Statement - April 13, 2023

Currently, more than 70 percent of our content is freely available — and we’d like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcasts free for everyone.

Subscribe to Semafor Healthcare for free.